Edited By Uwe Marx And Volker Sandig. Includes Bibliographical References And Index. Also Available In An Electronic Version. Mode Of Access: World Wide Web.
Human pluripotent stem cells for disease modelling and drug screening
✍ Scribed by Yves Maury; Morgane Gauthier; Marc Peschanski; Cécile Martinat
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 362 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0265-9247
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Considerable hope surrounds the use of disease‐specific pluripotent stem cells to generate models of human disease allowing exploration of pathological mechanisms and search for new treatments. Disease‐specific human embryonic stem cells were the first to provide a useful source for studying certain disease states. The recent demonstration that human somatic cells, derived from readily accessible tissue such as skin or blood, can be converted to embryonic‐like induced pluripotent stem cells (hiPSCs) has opened new perspectives for modelling and understanding a larger number of human pathologies. In this review, we examine the opportunities and challenges for the use of disease‐specific pluripotent stem cells in disease modelling and drug screening. Progress in these areas will substantially accelerate effective application of disease‐specific human pluripotent stem cells for drug screening.
📜 SIMILAR VOLUMES
## Abstract ## Objective To construct a humanized mouse model of systemic lupus erythematosus (SLE) that resembles the human disease in order to define the pathophysiology and targets for treatments. ## Methods We infused peripheral blood mononuclear cells (PBMCs) from SLE patients into BALB‐ RA